Patents by Inventor Mark Knuth

Mark Knuth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240092918
    Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Application
    Filed: February 3, 2023
    Publication date: March 21, 2024
    Inventors: Steven BENDER, Tracy CHARLTON, Anna GALKIN, Bernhard Hubert GEIERSTANGER, Scott Martin GLASER, Shailaja KASIBHATLA, Mark KNUTH, Sabine ROTTMANN, Sarah RUE, Glen SPRAGGON, Tetsuo UNO
  • Patent number: 11634497
    Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: April 25, 2023
    Assignee: NOVARTIS AG
    Inventors: Steven Bender, Tracy Charlton, Anna Galkin, Bernhard Hubert Geierstanger, Scott Martin Glaser, Shailaja Kasibhatla, Mark Knuth, Sabine Rottmann, Sarah Rue, Glen Spraggon, Tetsuo Uno
  • Publication number: 20220127321
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder.
    Type: Application
    Filed: August 26, 2021
    Publication date: April 28, 2022
    Inventors: Michael DiDonato, Bernhard Hubert Geierstanger, Tobias Junt, Mark Knuth, Shelly Meeusen, Carolina Nicole Simpson, Glen Spraggon, John Trauger
  • Patent number: 11136366
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: October 5, 2021
    Assignee: Novartis AG
    Inventors: Michael DiDonato, Bernhard Hubert Geierstanger, Tobias Junt, Mark Knuth, Shelly Meeusen, Carolina Nicole Simpson, Glen Spraggon, John Trauger
  • Publication number: 20210010013
    Abstract: The present disclosure provides fatty acid desaturase 2 (FAD2) genes and plants and/or plant cells bearing one or more mutations in two or more FAD2 genes; as well as methods of making and using such plants. In some embodiments, plants producing seed oil with high oleic acid content are provided.
    Type: Application
    Filed: April 4, 2019
    Publication date: January 14, 2021
    Applicants: Cibus US LLC, Cibus Europe, B.V.
    Inventors: Gregory F.W. GOCAL, Mark KNUTH
  • Publication number: 20200216548
    Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Application
    Filed: February 1, 2018
    Publication date: July 9, 2020
    Inventors: Steven BENDER, Tracy CHARLTON, Anna GALKIN, Bernhard Hubert GEIERSTANGER, Scott Martin GLASER, Shailaja KASIBHATLA, Mark KNUTH, Sabine ROTTMANN, Sarah RUE, Glen SPRAGGON, Tetsuo UNO
  • Publication number: 20190241636
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder.
    Type: Application
    Filed: October 18, 2018
    Publication date: August 8, 2019
    Inventors: Michael DiDonato, Bernhard Hubert Geierstanger, Tobias Junt, Mark Knuth, Shelly Meeusen, Carolina Nicole Simpson, Glen Spraggon, John Trauger
  • Patent number: 10144768
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 4, 2018
    Assignee: Novartis AG
    Inventors: Michael DiDonato, Bernhard Hubert Geierstanger, Tobias Junt, Mark Knuth, Shelly Meeusen, Carolina Nicole Simpson, Glen Spraggon, John Trauger
  • Patent number: 9796938
    Abstract: Provided herein are blends oils or fatty acids comprising more than 50% medium chain fatty acids, or the fatty acid alkyl esters thereof, and having low melting points. Such blends are useful as a fuel or as a starting material for the production of, for example, a biodiesel. Also provided genetically altered or modified plants, modified such that the amount of medium chain fatty acids generated by the plant are increased. Further provided is a method of predicting the melting point of a blend of fatty acid methyl esters and the use of such a method for identifying blends suitable for use as, for example, a biodiesel.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: October 24, 2017
    Assignee: NUCELIS INC.
    Inventors: Mark Knuth, Peter R. Beetham, Keith Walker, Greg F. W. Gocal
  • Publication number: 20170158747
    Abstract: The present disclosure provides antibody cytokine engrafted proteins that bind to and stimulate intracellular signaling through interleukin 10 receptor. Provided antibody cytokine engrafted proteins find use in enhancing anti-inflammatory cell responses, and reducing pro-inflammatory effects in the treatment, amelioration and prophylaxis of immune related disorders. Additionally provided are polynucleotides and vectors that encode antibody cytokine engrafted proteins and host cells capable of producing antibody cytokine engrafted proteins, as well as methods of combining antibody cytokine engrafted proteins with other therapeutics in treating immune related disorder.
    Type: Application
    Filed: December 1, 2016
    Publication date: June 8, 2017
    Inventors: Michael DIDONATO, Mark KNUTH, Shelly MEEUSEN, Glen SPRAGGON
  • Publication number: 20170051219
    Abstract: Provided herein are blends oils or fatty acids comprising more than 50% medium chain fatty acids, or the fatty acid alkyl esters thereof, and having low melting points. Such blends are useful as a fuel or as a starting material for the production of, for example, a biodiesel. Also provided genetically altered or modified plants, modified such that the amount of medium chain fatty acids generated by the plant are increased. Further provided is a method of predicting the melting point of a blend of fatty acid methyl esters and the use of such a method for identifying blends suitable for use as, for example, a biodiesel.
    Type: Application
    Filed: January 28, 2013
    Publication date: February 23, 2017
    Inventors: Mark Knuth, Peter R. Beetham, Keith Walker, Greg F.W. Gocal
  • Patent number: 8361173
    Abstract: Provided herein are blends oils or fatty acids comprising more than 50% medium chain fatty acids, or the fatty acid alkyl esters thereof, and having low melting points. Such blends are useful as a fuel or as a starting material for the production of, for example, a biodiesel. Also provided genetically altered or modified plants, modified such that the amount of medium chain fatty acids generated by the plant are increased. Further provided is a method of predicting the melting point of a blend of fatty acid methyl esters and the use of such a method for identifying blends suitable for use as, for example, a biodiesel.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: January 29, 2013
    Assignee: Nucelis Inc.
    Inventors: Mark Knuth, Peter R. Beetham, Keith Walker, Greg F. W. Gocal
  • Publication number: 20120073186
    Abstract: Provided herein are blends oils or fatty acids comprising more than 50% medium chain fatty acids, or the fatty acid alkyl esters thereof, and having low melting points. Such blends are useful as a fuel or as a starting material for the production of, for example, a biodiesel. Also provided genetically altered or modified plants, modified such that the amount of medium chain fatty acids generated by the plant are increased. Further provided is a method of predicting the melting point of a blend of fatty acid methyl esters and the use of such a method for identifying blends suitable for use as, for example, a biodiesel.
    Type: Application
    Filed: September 7, 2011
    Publication date: March 29, 2012
    Inventors: Mark Knuth, Peter R. Beetham, Keith Walker, Greg F. W. Gocal
  • Patent number: 8029579
    Abstract: Provided herein are blends oils or fatty acids comprising more than 50% medium chain fatty acids, or the fatty acid alkyl esters thereof, and having low melting points. Such blends are useful as a fuel or as a starting material for the production of, for example, a biodiesel. Also provided genetically altered or modified plants, modified such that the amount of medium chain fatty acids generated by the plant are increased. Further provided is a method of predicting the melting point of a blend of fatty acid methyl esters and the use of such a method for identifying blends suitable for use as, for example, a biodiesel.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: October 4, 2011
    Assignee: COH Inc.
    Inventors: Mark Knuth, Peter R. Beetham, Keith A. Walker, Gregory Francis William Gocal
  • Publication number: 20110003736
    Abstract: The subject invention concerns new classes of pesticidally active proteins and the polynucleotide sequences that encode these proteins. In preferred embodiments, these pesticidal proteins have molecular weights of approximately 40-50 kDa and of approximately 10-15 kDa.
    Type: Application
    Filed: June 30, 2010
    Publication date: January 6, 2011
    Applicant: Mycogen Corporation
    Inventors: Kenneth E. Narva, H. Ernest Schnepf, Mark Knuth, Michael R. Pollard, Guy A. Cardineau, George E. Schwab, Tracy Ellis Michaels, Stacey Finstad Lee, Paula Diehl, Joanna Dojillo, Lisa Stamp, Rod Herman
  • Patent number: 7790961
    Abstract: The subject invention concerns new classes of pesticidally active proteins and the polynucleotide sequences that encode these proteins. In preferred embodiments, these pesticidal proteins have molecular weights of approximately 40-50 kDa and of approximately 10-15 kDa.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: September 7, 2010
    Assignee: Hycogen Corporation
    Inventors: Kenneth E. Narva, H. Ernest Schnepf, Mark Knuth, Michael R. Pollard, Guy A. Cardineau, George E. Schwab, Tracy Ellis Michaels
  • Patent number: 7355003
    Abstract: The subject invention concerns new classes of pesticidally active proteins and the polynucleotide sequences which encode these proteins. More specifically, in preferred embodiments, pesticidal proteins of approximately 40-50 kDa and of approximately 10-15 kDa are used for controlling corn rootworms. Also described are novel pesticidal isolates of Bacillus thuringiensis.
    Type: Grant
    Filed: January 18, 2005
    Date of Patent: April 8, 2008
    Assignee: Mycogen Corporation
    Inventors: Kenneth E. Narva, H. Ernest Schnepf, Mark Knuth, Michael R. Pollard, Guy A. Cardineau, George E. Schwab, Tracy Ellis Michaels
  • Publication number: 20070265205
    Abstract: The subject invention concerns new classes of pesticidally active proteins and the polynucleotide sequences that encode these proteins. In preferred embodiments, these pesticidal proteins have molecular weights of approximately 40-50 kDa and of approximately 10-15 kDa.
    Type: Application
    Filed: June 29, 2007
    Publication date: November 15, 2007
    Inventors: Kenneth Narva, H. Schnepf, Mark Knuth, Michael Pollard, Guy Cardineau, George Schwab, Tracy Michaels, Stacey Lee, Paula Diehl, Joanna Dojillo, Lisa Stamp, Rod Herman
  • Patent number: 7247613
    Abstract: The subject invention concerns new classes of pesticidally active proteins and the polynucleotide sequences that encode these proteins. In preferred embodiments, these pesticidal protein have molecular weights of approximately 40–50 kDa and of approximately 10–15 kDa.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: July 24, 2007
    Assignee: Mycogen Corporation
    Inventors: Kenneth E. Narva, H. Ernest Schnepf, Mark Knuth, Michael R. Pollard, Guy A. Cardineau, George E. Schwab, Tracy Ellis Michaels, Stacey Finstad Lee, Paula Diehl, Joanna Dojillo, Lisa Stamp, Rod Herman
  • Publication number: 20050155112
    Abstract: The subject invention concerns new classes of pesticidally active proteins and the polynucleotide sequences which encode these proteins. More specifically, in preferred embodiments, pesticidal proteins of approximately 40-50 kDa and of approximately 10-15 kDa are used for controlling corn rootworms. Also described are novel pesticidal isolates of Bacillus thuringiensis.
    Type: Application
    Filed: January 18, 2005
    Publication date: July 14, 2005
    Applicant: Mycogen Corporation
    Inventors: Kenneth Narva, H. Schnepf, Mark Knuth, Michael Pollard, Guy Cardineau, George Schwab, Tracy Michaels, Stacey Lee, Paula Burmeister, Joanna Dojillo